Inicio › Leucemia linfoblástica aguda › California › Los Angeles
Ensayos clínicos de Leucemia linfoblástica aguda en Los Angeles, CA
14 estudios para Leucemia linfoblástica aguda buscan participantes en centros de Los Angeles y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Reclutando
- Children's Hospital of Los Angeles, Los Angeles
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
ReclutandoFase 2
- Children's Hospital Los Angeles, Los Angeles
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Children's Hospital Los Angeles, Los Angeles
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
ReclutandoFase 2
- Children's Hospital Los Angeles, Los Angeles
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
ReclutandoEstudio observacional
- University of California Los Angeles, Los Angeles
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
ReclutandoFase 1
- Cedars-Sinai Medical Center, Los Angeles
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- UCLA, Los Angeles
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
ReclutandoFase 1/2
- Children's Hospital Los Angeles, Los Angeles
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
ReclutandoEstudio observacional
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
ReclutandoFase 3
- Ascentage Investigative Site #1134, Los Angeles
- Ascentage Investigative Site #1059, Los Angeles
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
ReclutandoFase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Bright Ideas - CIN Feasibility Study
Reclutando
- Children's Hospital Los Angeles, Los Angeles
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
Reclutando
- Jackie and Gene Autry Orthopedic Center, CHLA, Los Angeles
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
ReclutandoFase 1
- Children's Hospital Los Angeles, Los Angeles
Ensayos de Leucemia linfoblástica aguda en otras ciudades
- Houston, TX28 estudios
- New York City, NY24 estudios
- Baldwin Park, CA21 estudios
- Seattle, WA21 estudios
- Chicago, IL19 estudios
- Atlanta, GA19 estudios
- Memphis, TN16 estudios
- Philadelphia, PA16 estudios
- Washington, DC16 estudios
- Boston, MA15 estudios
- Durham, NC13 estudios
- Mountain View, CA13 estudios
Otros estudios en Los Angeles
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer (todos los tipos)73 estudios
- Cáncer de seno72 estudios
- Cáncer de próstata61 estudios
- Cáncer del colon y del recto59 estudios
- Cáncer metastásico57 estudios
- Cáncer de ovario50 estudios
- Cáncer de pulmón45 estudios
- Carcinoma de células escamosas de cabeza y cuello42 estudios
- Cáncer de páncreas35 estudios
- Cáncer de endometrio34 estudios
- Melanoma34 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.